Compare Amphastar Pharmaceuticals Inc (AMPH) vs Oatly Group AB - ADR (OTLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Oatly Group AB - ADR — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Oatly Group AB - ADR trades at $12.93 (market cap $421.56M). The key difference: Amphastar Pharmaceuticals Inc is far larger — about 2× Oatly Group AB - ADR's market cap, and Oatly Group AB - ADR is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | OTLY | |
|---|---|---|
Market Cap | $863.95M | $421.56M |
Sector | Health | Consumer Staples |
52-Week High | $30.81 | $18.54 |
52-Week Low | $16.87 | $8.03 |
Enterprise Value | $1.26B | $925.97M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Oatly (OTLY) trades at $13.72, up 0.22% with a bullish technical signal driven by moving averages and oversold RSI levels. Revenue growth improved to $862.46M in 2025, though net losses persist at -$152.77M. Recent Q2 2026 results beat EPS expectations, prompting a raised full-year revenue outlook to $925M, fueling a 29% stock surge on July 22, 2026 (GlobeNewsWire). The company shows progress toward adjusted EBITDA positivity, but cash burn remains a concern.
The outlook hinges on execution of margin expansion and cash flow improvement. Risks include high debt-to-asset ratio (66.53% in 2025) and intense competition. Analyst consensus is mixed with 44% buy ratings, but institutional sentiment is cautious due to profitability challenges. Upside potential exists if Oatly achieves sustained EBITDA positivity and reduces cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Oatly Group AB - ADR
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, Icecreams, among others. It caters to Sweden, Germany, United Kingdom, Netherlands, North America, Finland, and other markets.
Read more on OTLY →
